Zylox-Tonbridge repurchases 79,000 H shares for HK$1.89 million, treasury stock rises to 7.20 million

Bulletin Express03-25 19:41

On 25 March 2026, Zylox-Tonbridge Medical Technology Co., Ltd. conducted an on-market buyback of 79,000 H shares on the Hong Kong Stock Exchange, paying between HK$23.56 and HK$24.10 per share. The aggregate consideration totalled HK$1.89 million.

Following the transaction: • Issued shares outstanding (excluding treasury shares) fell by 79,000 to 329.15 million. • Treasury shares increased to 7.20 million, while total issued shares remained at 336.35 million. • The repurchased amount represents 0.0234 % of the company’s issued share capital prior to the purchase. • All 79,000 shares are being held as treasury stock; none have been cancelled.

Buybacks are executed under the repurchase mandate approved on 30 May 2025, which authorises Zylox-Tonbridge to repurchase up to 31.96 million shares. Cumulative repurchases under this mandate now stand at 4.39 million shares, or 1.34 % of the company’s issued shares at the mandate date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 24 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment